Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Gene therapy side effects prompt search for new delivery methods

3 years ago

EMA developing physician guidance for potential liver damage after taking Zolgensma

3 years ago

Vertex gets more precise with Arbor in expanded gene editing pact

3 years ago

4D Molecular pauses enrollment in Fabry trials after kidney problems in three patients

3 years ago

Voyager goes big, securing multi-billion dollar gene therapy development deal with Neurocrine

3 years ago

BioMarin buffs up data on hemophilia A gene therapy as FDA decision deadline approaches

3 years ago

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks

3 years ago

Updated: Sickle cell gene editing startup halts trial after flagging serious side effect in first patient

3 years ago

On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M

3 years ago

Intellia plots pivotal trials for lead programs as it lays out key objectives

3 years ago

With focus on neglected eye diseases, Opus buys two gene therapies from Iveric Bio

3 years ago

Celyad scraps one final clinical CAR-T program as clock ticks

3 years ago

Taysha CEO steps down after patent fights with patient families, job cuts

3 years ago

FDA lifts hold on studies of bluebird's sickle cell gene therapy in adolescents

3 years ago

Sanofi plucks three more NK cell engagers from French biotech partner, putting down €25M cash

3 years ago

Scoop: A2 Biotherapeutics raises $62M for solid tumor cell therapies

3 years ago

FDA approves Ferring's new gene therapy for bladder cancer

3 years ago

EMA recommends hemophilia B gene therapy for approval, denies Y-mAbs neuroblastoma drug

3 years ago

#ASH22 Recap: Leading hematology experts talk top readouts; Fireside chat with Novo Nordisk's Ludovic Helfgott; More

3 years ago

With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial

3 years ago

Paul McKenzie to take the reins of CSL as new CEO in March

3 years ago

#ASH22: Bristol Myers reports next-gen CAR-T data as rival’s bispecific heads to FDA, and gives alnuctamab another shot

3 years ago

#ASH22: J&J touts first PhII results of next-gen multiple myeloma antibody

3 years ago

Autolus tips its hand, bags $220M as CAR-T showdown with Gilead looms

3 years ago

First page Previous page 22 23 242526 27 28 Next page Last page